Humana
HUM
$359.13
-0.44%
Humana Inc. is one of the largest private health insurers in the United States, operating within the Medical - Healthcare Plans industry. The company has carved out a distinct market position as a specialized player in government-sponsored health programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program, complemented by healthcare services like primary care and pharmacy benefit management. The current investor narrative is dominated by the impact of regulatory changes on Medicare Advantage payments, with recent news highlighting a significant stock rally following a favorable 2027 payment update from CMS, which has improved sector-wide revenue visibility and sentiment, positioning Humana as a key beneficiary of this policy-driven catalyst.…
HUM
Humana
$359.13
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating: Hold. The core thesis is that while Humana benefits from a powerful regulatory catalyst and trades at a compelling valuation discount, severe earnings volatility and cash flow instability warrant caution, making the stock suitable only for risk-tolerant investors who can stomach high quarterly uncertainty.
Supporting evidence for this Hold rating includes: 1) A deeply discounted valuation with a PS ratio of 0.24 versus its historical range of 0.95-2.87, 2) Robust 11.3% YoY revenue growth demonstrating underlying business strength, 3) A favorable debt profile with a D/E of 0.73, and 4) Explosive price momentum of 112% over three months driven by the CMS catalyst. However, these positives are counterbalanced by a net loss of $796 million in the latest quarter, negative operating cash flow of -$1.65 billion, and a wide dispersion in analyst revenue estimates signaling high uncertainty.
The two biggest risks that could invalidate a neutral stance are a failure to stabilize margins (if gross margins remain below 12% for multiple quarters) and a sustained deterioration in liquidity (if operating cash flow remains deeply negative). This Hold would upgrade to a Buy if the company demonstrates consecutive quarters of positive net income and operating cash flow, confirming margin stability. It would downgrade to a Sell if revenue growth decelerates sharply below 5% or if the stock fails to hold key support after its massive run. Relative to its history and the improved policy backdrop, the stock appears fairly valued to slightly undervalued on a sales basis, but overvalued on a trailing P/E basis given recent losses.
Sign up to view all
HUM 12-Month Price Forecast
Humana presents a complex, binary investment profile post its policy-driven rally. The valuation is compellingly cheap on a sales basis, and the regulatory overhang has lifted. However, the company has not yet demonstrated an ability to translate top-line growth into stable profits and cash flow, as evidenced by the severe Q4 loss. The neutral stance reflects this standoff between catalyst and execution. The stance would upgrade to bullish on evidence of margin stabilization for two consecutive quarters. It would turn bearish if the next earnings report shows continued severe cash burn or a guidance reduction. The base case of consolidation is most likely, as the market digests the rally and awaits proof of fundamental improvement.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $466.87 and implied upside of +30.0% versus the current price.
Average Target
$466.87
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$287 - $467
Analyst target range
Analyst coverage is limited, with only 7 analysts providing estimates, indicating this is a stock with less institutional research scrutiny which can lead to higher volatility. The consensus sentiment appears mixed, as the limited institutional ratings data from February 2026 shows a distribution of actions including Sell (Goldman Sachs), Hold/Equal Weight (multiple firms), and Buy (Jefferies, Guggenheim), with no clear overwhelming bullish or bearish tilt. The target price range implied by revenue estimates is wide, with a low of $196.36 billion and a high of $214.11 billion for estimated revenue, signaling high uncertainty among analysts regarding the company's future growth trajectory and the sustainability of its recent rally driven by Medicare payment news.
Bulls vs Bears: HUM Investment Factors
The investment debate for Humana is a classic clash between powerful valuation and sentiment catalysts versus deep-seated concerns over fundamental execution. The bull side currently has stronger evidence, anchored by a historic valuation discount (PS of 0.24), a transformative regulatory catalyst (CMS payment update), and explosive price momentum (112% in 3 months). However, the bear case is grounded in severe and persistent operational weaknesses, namely extreme earnings volatility (Q4 net loss of $796M) and negative quarterly cash flow. The single most important tension is whether the recent policy-driven rally and low valuation multiple can be sustained in the face of demonstrably inconsistent profitability. The thesis hinges on whether management can translate improved revenue visibility into more stable margins and cash generation.
Bullish
- Historic Valuation Discount: Humana trades at a trailing PS ratio of 0.24 and an EV/Sales of 0.27, which is near the bottom of its historical range (0.95 to 2.87) and a substantial discount to typical healthcare plan sector multiples. This deep discount, despite a 112% three-month rally, suggests significant embedded pessimism and a potential value opportunity if sentiment improves.
- The stock's 112% surge over three months is directly tied to a favorable 2027 Medicare Advantage payment update from CMS, which significantly improved sector-wide revenue visibility. As a company with nearly all membership in government-sponsored programs, Humana is a primary beneficiary of this regulatory tailwind.
- Strong Revenue Growth Trajectory: The company delivered 11.3% year-over-year revenue growth in Q4 2025, continuing a trend of solid top-line expansion driven by its core Insurance Segment. This demonstrates underlying demand strength in its specialized Medicare/Medicaid niche, even amidst profitability volatility.
- Manageable Leverage and Positive TTM FCF: Humana's debt-to-equity ratio of 0.73 indicates moderate leverage, and it generated $375 million in trailing twelve-month free cash flow. This provides a financial cushion and suggests the company can fund operations internally, despite recent quarterly cash flow volatility.
Bearish
- Severe Earnings and Margin Volatility: Profitability is highly inconsistent, swinging from a net income of $1.24 billion in Q1 2025 to a net loss of $796 million in Q4 2025, with gross margins collapsing from 17.37% to 11.67% over the same period. This extreme volatility, tied to medical cost trends, makes forecasting earnings exceptionally difficult and undermines investor confidence.
- Negative Operating Cash Flow in Latest Quarter: Despite positive TTM FCF, the most recent quarter saw operating cash flow turn deeply negative at -$1.65 billion, highlighting severe working capital volatility. This raises questions about the sustainability of internal funding and the company's near-term liquidity, especially with a tight current ratio of 0.72.
- Analyst Uncertainty and Limited Coverage: Only 7 analysts provide estimates, indicating less institutional scrutiny and potentially higher volatility. Furthermore, the implied revenue target range is wide ($196B to $214B), and ratings are mixed (Sell, Hold, Buy), signaling high uncertainty about the company's future trajectory post-rally.
- Technically Overextended Near 52-Week High: Trading at $360.65, the stock is approximately 95% of the way to its 52-week high of $380.86 after a 112% surge. This positioning suggests the rally may be overextended, increasing vulnerability to a technical pullback or profit-taking, especially if the next catalyst disappoints.
HUM Technical Analysis
The stock is in a powerful recovery and uptrend, having surged 112.27% over the past three months and 48.17% over the past year, decisively reversing a severe drawdown. As of the latest close of $360.65, the price is trading near the top of its 52-week range, approximately 95% of the way towards its 52-week high of $380.86, indicating strong momentum but also potential overextension and vulnerability to a pullback. Recent short-term momentum is exceptionally strong, with a 16.13% gain over the past month, which significantly outpaces the S&P 500's 0.74% gain, confirming the acceleration of the longer-term recovery trend; this is further evidenced by the stock's relative strength of 15.39 against the market over the same period. Key technical levels are clear, with immediate resistance at the 52-week high of $380.86 and major support at the 52-week low of $163.11; a breakout above resistance would signal a continuation of the powerful uptrend, while a failure could lead to consolidation. The stock's beta of 0.77 indicates it has been less volatile than the broader market during this period, which is notable given the magnitude of its recent moves and suggests the rally has been driven by strong, sustained buying pressure rather than speculative frenzy.
Beta
0.77
0.77x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$381
Price range past year
Annual Return
+53.0%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +16.6% | -1.6% |
| 3m | +106.1% | +11.7% |
| 6m | +38.5% | +6.3% |
| 1y | +53.0% | +22.2% |
| ytd | +35.8% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth is robust but masked by significant quarterly volatility in profitability; the most recent Q4 2025 revenue was $32.52 billion, representing an 11.3% year-over-year growth, continuing a multi-quarter trend of solid top-line expansion primarily driven by its core Insurance Segment, which contributed $31.34 billion. Profitability is highly inconsistent, with the company swinging from a net income of $1.24 billion and a gross margin of 17.37% in Q1 2025 to a net loss of $796 million and a gross margin of 11.67% in Q4 2025, indicating severe margin compression and earnings volatility tied to medical cost trends and potential reserve adjustments. The balance sheet and cash flow position show a mixed financial health picture: the debt-to-equity ratio is a manageable 0.73, indicating moderate leverage, but liquidity is tight with a current ratio of 0.72; trailing twelve-month free cash flow is positive at $375 million, yet the most recent quarter saw operating cash flow turn deeply negative at -$1.65 billion, highlighting significant working capital volatility and raising questions about the sustainability of internal funding for growth.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company's net income was negative in the most recent quarter, we lead with the Price-to-Sales (PS) ratio, which is more stable. Humana's trailing PS ratio is 0.24, and its forward valuation is implied by an EV/Sales of 0.27, suggesting the market is pricing the stock at a very low multiple of revenue despite the recent price surge. Compared to industry averages, this PS ratio of 0.24 represents a substantial discount to the typical healthcare plans sector, which often trades at higher sales multiples; this deep discount likely reflects the market's significant concerns over earnings volatility and margin pressures seen in recent quarterly results. Historically, the current PS ratio of 0.24 is near the very bottom of its own historical range, which has spanned from approximately 0.95 to over 2.87 in recent years; trading at such depressed historical levels suggests the market is pricing in a pessimistic scenario of sustained margin challenges, presenting a potential value opportunity if the company can demonstrate more consistent execution.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced and center on extreme earnings volatility and liquidity concerns. The company's profitability is highly unstable, as evidenced by the swing from a $1.24 billion net income in Q1 2025 to a $796 million loss in Q4 2025, with gross margins compressing by 570 basis points. This makes the stock difficult to value on an earnings basis. Furthermore, while TTM free cash flow is positive at $375 million, the most recent quarter saw operating cash flow plunge to -$1.65 billion, indicating significant working capital swings that could pressure the balance sheet, especially given a tight current ratio of 0.72.
Market & Competitive Risks stem from its policy-dependent business model and the potential for valuation compression after a massive rally. The company's revenue is almost entirely tied to government Medicare/Medicaid programs, making it vulnerable to future regulatory changes that could reverse the recent positive sentiment. From a valuation perspective, while the PS ratio of 0.24 is low historically, the stock's 112% surge in three months to near its 52-week high leaves it vulnerable to profit-taking and sector rotation, particularly if growth expectations are not met. Its beta of 0.77 suggests it is less volatile than the market, but the magnitude of its recent move is atypical for such a beta.
Worst-Case Scenario involves a combination of adverse medical cost trends and a negative shift in regulatory sentiment. If medical costs spike unexpectedly, leading to another significant quarterly loss, and subsequent CMS updates are less favorable, investor confidence in the recent turnaround narrative could collapse. This could trigger analyst downgrades from the currently mixed cohort and a rapid de-rating. A realistic downside could see the stock retrace a substantial portion of its rally, potentially testing the $250-$275 range (a ~30% decline from current levels) or, in a severe scenario, revisiting the psychological support near its 52-week low of $163.11, representing a catastrophic loss of over 55%.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company's profitability is highly unstable, swinging from large profits to significant losses quarter-to-quarter, as seen in the $796M Q4 2025 loss. 2) Regulatory/Political Risk: Nearly all revenue is tied to U.S. government programs, making it vulnerable to changes in Medicare/Medicaid payment policies. 3) Liquidity & Cash Flow Risk: The most recent quarter showed operating cash flow of -$1.65 billion, raising concerns about working capital management. 4) Valuation Compression Risk: After a 112% surge, the stock is trading near its 52-week high and is vulnerable to a sharp pullback if growth expectations are not met.
The 12-month forecast is bifurcated, with a high degree of uncertainty. The base case (50% probability) sees the stock consolidating between $320 and $380 as it digests its massive rally. The bull case (30% probability), targeting $380-$420, requires proof of sustained profitability improvement. The bear case (20% probability), targeting $250-$320, involves another earnings miss and a sentiment reversal. The most likely scenario is the base case of range-bound trading, as the market awaits concrete evidence that the company can convert its regulatory win and revenue growth into stable earnings.
HUM presents a paradoxical valuation. On a Price-to-Sales basis, it appears profoundly undervalued, trading at a PS of 0.24, which is near the bottom of its historical range (0.95-2.87) and a discount to sector peers. This suggests the market is pricing in sustained margin challenges. However, on an earnings basis, it is difficult to assess due to recent losses. Overall, the stock is fairly valued to slightly undervalued relative to its improved revenue visibility and policy backdrop, but this discount is justified until the company proves it can generate stable profits.
HUM is a speculative buy, suitable only for investors with a high risk tolerance and a tactical mindset. The recent 112% rally driven by a favorable Medicare payment update has improved the outlook, and the stock trades at a deeply discounted PS ratio of 0.24. However, it comes with significant risks, including severe earnings volatility (a $796M loss in Q4 2025) and negative quarterly cash flow. It could be a good buy for those betting on a sustained operational turnaround, but it is not a good buy for investors seeking stability or consistent income.
HUM is more suitable for a medium-term tactical investment (6-18 months) than for a traditional long-term buy-and-hold strategy. Its low beta of 0.77 and modest dividend yield of 1.4% do not align with typical income or low-volatility long-term holds. The investment thesis is currently driven by a specific regulatory catalyst and the potential for a valuation re-rating if quarterly execution improves. Given the high earnings volatility and policy dependence, investors should be prepared to act on quarterly results. A minimum holding period through at least the next two earnings reports is advised to assess whether the operational turnaround is taking hold.